Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management
- PMID: 17329180
- DOI: 10.1016/j.pcad.2006.10.002
Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management
Abstract
First isolated in the early 1960s, doxorubicin (DOX) remains among the most effective anticancer drug ever developed. However, this drug has proven to be a double-edged sword because it also causes a cardiomyopathy that leads to a form of congestive heart failure that is usually refractory to common medications. It is hoped that a better understanding of the mechanisms underlying DOX's cardiotoxicity will enable development of therapies with which to prevent and/or treat the heart failure it causes. Suggested contributors to DOX-induced cardiomyopathy include formation of reactive oxygen species, apoptosis, inhibited expression of cardiomyocyte-specific genes, and altered molecular signaling. And taking these various contributors into consideration, a variety of approaches aimed at preventing or mitigating the cardiotoxicity of DOX have been tried, but so far, the ability of these treatments to protect the heart from damage has been limited. That said, one recent approach that shows promise is adjuvant therapy with a combination of hematopoietic cytokines, including erythropoietin, granulocyte colony-stimulating factor, and thrombopoietin. We suggest this approach to preventing DOX-induced cardiomyopathy is worthy of serious consideration for clinical use.
Similar articles
-
Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.Circulation. 2006 May 9;113(18):2211-20. doi: 10.1161/CIRCULATIONAHA.105.560250. Epub 2006 May 1. Circulation. 2006. PMID: 16651473
-
Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.J Pharmacol Exp Ther. 2008 Jan;324(1):160-9. doi: 10.1124/jpet.107.125773. Epub 2007 Oct 10. J Pharmacol Exp Ther. 2008. PMID: 17928571
-
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.J Pharm Pharmacol. 2004 Jun;56(6):757-68. doi: 10.1211/0022357023565. J Pharm Pharmacol. 2004. PMID: 15231041
-
Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.Med Res Rev. 2014 Jan;34(1):106-35. doi: 10.1002/med.21280. Epub 2013 Mar 11. Med Res Rev. 2014. PMID: 23494977 Review.
-
Pathogenesis and prevention of doxorubicin cardiomyopathy.Tsitologiia. 1997;39(10):928-37. Tsitologiia. 1997. PMID: 9505340 Review.
Cited by
-
Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2.Oxid Med Cell Longev. 2020 Aug 1;2020:3598715. doi: 10.1155/2020/3598715. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32831995 Free PMC article.
-
Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.Biol Open. 2016 Oct 15;5(10):1362-1370. doi: 10.1242/bio.020362. Biol Open. 2016. PMID: 27543060 Free PMC article.
-
Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.J Med Chem. 2012 Jul 26;55(14):6595-607. doi: 10.1021/jm300714p. Epub 2012 Jul 17. J Med Chem. 2012. PMID: 22742660 Free PMC article.
-
HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage.Cell Biol Toxicol. 2024 Jul 15;40(1):55. doi: 10.1007/s10565-024-09893-2. Cell Biol Toxicol. 2024. PMID: 39008169 Free PMC article. Review.
-
Breviscapine remodels myocardial glucose and lipid metabolism by regulating serotonin to alleviate doxorubicin-induced cardiotoxicity.Front Pharmacol. 2022 Sep 27;13:930835. doi: 10.3389/fphar.2022.930835. eCollection 2022. Front Pharmacol. 2022. PMID: 36238546 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical